Target intelligence / Profile preview

Phosphodiesterase 6A, cGMP-specific, rod, alpha subunit (PDE6A)

Target
PDE6A
Molecular classification
Enzyme, Phosphodiesterase, Class I phosphodiesterase
01

Overview

Phosphodiesterase 6A, cGMP-specific, rod, alpha subunit (PDE6A) is an enzyme highly expressed in the outer segments of retinal rod photoreceptors. It forms the catalytic alpha subunit of the PDE6 holoenzyme, which functions as the central effector in the phototransduction cascade. Upon light activation, PDE6A associates with other subunits (beta and gamma) to hydrolyze cyclic GMP (cGMP), causing a rapid decrease in intracellular cGMP concentrations. This decline results in the closure of cGMP-gated ion channels, hyperpolarization of the photoreceptor cell, and transmission of the visual signal. Mutations in the PDE6A gene disrupt these processes and are a known cause of autosomal recessive retinitis pigmentosa and related inherited retinal diseases. While the catalytic mechanism and regulatory interactions of PDE6A are well characterized, there are currently no approved drugs that selectively target this subunit; therapies are primarily supportive, with gene therapy approaches in development[2][4][5].

Other names
PDE6AcGMP-specific 3',5'-cyclic phosphodiesterase subunit alphaRod cGMP phosphodiesterase alpha subunit
02

Mechanism of action

Inhibition of cGMP hydrolysis (for phosphodiesterase inhibitors acting on this class, although these are not PDE6A-specific); Restoration of gene function (for gene therapies targeting PDE6A mutations in retinal diseases[5][2])

03

Biological functions

Signal transductionPhototransductionHydrolysis of cGMPVisual processing
04

Disease associations

Retinal degenerative diseaseRetinitis pigmentosaOther inherited retinal dystrophies
05

Safety considerations

Non-specific inhibition of PDE6 by drugs such as sildenafil can cause transient visual side effects (e.g., changes in color vision, blurred vision)[5].Targeted therapies must avoid interfering with normal phototransduction, as altered PDE6A function can profoundly impact vision.Gene therapy poses its own safety and efficacy challenges (e.g., immunogenicity, off-target effects[5]).
06

Interacting drugs

There are currently no approved drugs directly targeting PDE6A; however, PDE inhibitors (e.g., sildenafil) broadly target the phosphodiesterase family but are not specific to PDE6A[5][4].

2 more in the full profile.

07

Biomarkers

PDE6A gene mutation status (for patient selection in gene therapy for inherited retinal diseases such as retinitis pigmentosa[2])Rod photoreceptor function, as assessed by electroretinography (ERG)[2][5]

Beyond the preview

Go deeper on Phosphodiesterase 6A, cGMP-specific, rod, alpha subunit (PDE6A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphodiesterase 6A, cGMP-specific, rod, alpha subunit (PDE6A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call